TABLE 2

FROM:

Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study)

Wajeh Y Qunibi, Robert E Hootkins, Laveta L McDowell, Micah S Meyer, Matthias Simon, Rodolfo O Garza, Russell W Pelham, Mark V B Cleveland, Larry R Muenz, David Y He and Charles R Nolan

Table 2. Details of repeated measures logistic regression models for primary "goal attained" outcomes

	Phosphorusa		Calciumb		Ca P productc
Covariates	Parameter estimate	P value	Parameter estimate	P value	Parameter estimate	P value
Main effects
Intercept	-0.886	0.64	-4.585	0.21	-1.600	0.39
Drug: calcium acetate	0.862	0.0058	0.791	0.31	0.769	0.0097
Week	0.563	0.0005	-0.244	0.34	0.399	0.012
Week-squared	-0.051	0.0020	0.044	0.14	-0.034	0.044
Baseline outcome	-0.367	0.0004	0.732	0.010	-0.033	0.0014
Baseline iPTH (log10)	1.126	0.11	-0.053	0.94	1.005	0.11
Age	0.016	0.24	-0.004	0.76	0.008	0.50
Gender: female	-0.269	0.42	-0.174	0.62	-0.201	0.53
Weight	-0.009	0.26	-0.002	0.76	-0.004	0.55
Center	-0.589	0.076	0.007	0.98	-0.319	0.32
Interactiond between drug (calcium acetate) and Week			0.165	0.66
Week-squared			-0.043	0.31

^a Goal serum phosphorus 5.5 mg/dL.

^b Goal serum calcium equals 8.5–11 mg/dL.

^c Goal serum calcium phosphorus product 55 mg²/dL².

^d Although individual interaction term was not significant, the combined interaction effect of two terms was significant at P value of 0.019.